[CH2:1]([NH:4][CH:5]1[CH2:13][C:12]2[C:7](=[CH:8][CH:9]=[C:10]([C:14]3[CH:15]=[CH:16][C:17](=[O:20])[NH:18][N:19]=3)[CH:11]=2)[CH2:6]1)[CH2:2][CH3:3].Br.Cl[C:23]([O:25][CH2:26][CH:27]([CH3:29])[CH3:28])=[O:24]>>[CH2:1]([N:4]([CH:5]1[CH2:13][C:12]2[C:7](=[CH:8][CH:9]=[C:10]([C:14]3[CH:15]=[CH:16][C:17](=[O:20])[NH:18][N:19]=3)[CH:11]=2)[CH2:6]1)[C:23]([O:25][CH2:26][CH:27]([CH3:29])[CH3:28])=[O:24])[CH2:2][CH3:3]2-Propylamino-5-[pyridazin-3(2H)-on-6-yl]indane·hydrobromide and isobutyl chloroformate were treated in the same manner as in Example 51 to obtain 2-(N-propyl-N-isobutoxycarbonylamino)-5-[pyridazin-3(2H)-on-6-yl]indane.
Loading…